<!DOCTYPE html>
<html lang="en">
<head>
  <!-- Google tag (gtag.js) --> <script async src="https://www.googletagmanager.com/gtag/js?id=G-KKS2Y8FR6L"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-KKS2Y8FR6L'); </script>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="../figures/favicon.png" type="image/x-icon">
  <title>DUB</title>
  <link rel="stylesheet" href="/style.css">
  <link rel="stylesheet" href="/notes.css">
</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="/index.html">
    <div class="home-navigation">
      M
    </div>
  </a>

  <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="/index.html">Home</a>
      </li>
      <li class="menu__item">
        <a class="menu__link" href="/about-temp.html">About</a>
      </li>
      
     
      

      <li class="menu__item">
        <a class="menu__link" href="#0">Projects</a>
        <ul class="submenu">
          <li class="menu__item">
            <a class="menu__link" href="/404.html">Surgery</a>
          </li>
          <li class="menu__item">
            <a class="menu__link" href="/404.html">Pediatrics</a>
          </li>
        </ul>
      </li>
    </ul>
  </nav>
  
  <main class="page-container">
    <div class="contribute-cta">
      <p>Help make this betterðŸ’œ</p>
      <span><a href="/contribute.html">Contribute here</a> </span>
    </div>

    <h1>Dysfunctional uterine bleeding</h1>
  
    <!-- <div class="author-flex">
      <div class="author-img">
        <img  src="/contributors/vt1.jpeg" alt="">
      </div>
      <div>
        <h2 class="name">Compiled by Victortayo</h2>
        <p class="updated">last updated, Oct 2022</p>
      </div>
    </div> -->

    <article class="notes">
        <a id='top'></a>
    <article>
    <!-- <h2 class='title'>Outline</h2> -->
    <label class="trigger outline">
        <input type="checkbox" class="checkbox checkbox--red" /> Show/hide outline
        <div class="msg">
         <ol>
            <li><a href="#header-1">Introduction</a></li>
            <li><a href="#header-2">Types/classification</a></li>
            <li><a href="#header-3">Clinical presentation</a></li>
            <li><a href="#header-4">Differential diagnosis</a></li>
            <li><a href="#header-5">Investigations</a></li>
            <li><a href="#header-6">Treatments</a></li>
         </ol>
        </div>
      </label>
        <section id='header-1'>
            <header>
            <h2>     
                <a aria-hidden='true' href='#header-1'>Introduction</a>
            </h2>
            </header>
            <div class='body'>
                <p>Dysfunctional uterine bleeding (DUB) is classically defined as abnormal (excessively heavy, scanty, prolonged, frequent or infrequent) bleeding of uterine origin that is not caused by pregnancy or recognizable pelvic or systemic disease.</p>
                <p>Up to 20% of women will experience irregular cycles in their lifetimes.</p>
                <p>It is a <span class="underlined--offset">diagnosis of exclusion</span> i.e. it is only diagnosed after the most probable causes have been ruled out by appropriate investigations. Causes such as: </p>
                <ul>
                    <li>Pregnancy</li>
                    <li>Medications </li>
                    <li>Iatrogenic causes </li>
                    <li>Genital tract pathology </li>
                    <li>Malignancy</li>
                    <li>Systemic diseases e.g. bleeding disorders</li>

                </ul>
        </section>
        <section id='header-2'>
            <header>
            <h2>
                <a aria-hidden='true' href='#header-2'>Types/classification</a>
            </h2>
            </header>
            <div class='body'>
                <ol>
                    <li>Anovulatory</li>
                    <li>Ovulatory</li>
                </ol>
                <p>Approximately <span class="special-text-3">90% </span> of dysfunctional uterine bleeding cases result from anovulation, and <span class="special-text-3">10% </span> of cases occur with ovulatory cycles.</p>
                <section id='heading-2-1'>
                    <header>
                    <h3>
                        <a aria-hidden href='#heading-2-1'>Anovulatory DUB</a>
                    </h3>
                    </header>
                    <div class='body'>
                        <p>Usually results from <span class="underlined--offset">disordered functioning of the hypothalamic-pituitary-ovarian (HPO) axis</span>.</p>
                        <p>Occurs most often in <span class="underlined--offset">women at the extreme ends of their reproductive lifetime</span>. </p>
                        <p>Both <span class="special-text">perimenarchal</span> and <span class="special-text">perimenopausal</span> women have several anovulatory cycles per year, it is therefore a common problem in adolescent females as well as elderly women.</p>
                        <p>Other causes/risk factors for anovulatory uterine bleeding include- </p>
                        <ul>
                            <li>Excessive exercise</li>
                            <li>Emotional stress</li>
                            <li>Eating disorders (bulimia and anorexia)</li>
                            <li>Obesity</li>
                            <li>Polycystic ovarian syndrome (PCOS)</li>
                            <li>Hyperprolactinemia </li>
                            <li>Thyroid disease</li>
                        </ul>
                        <p>Most cannot be classified as DUB, some are gray areas.</p>
                        <figure>
                            <img src="/figures/figures-01.png" alt="">
                            <figcaption>fig. I. Pathway of action of hormones for normal menstrual function.</figcaption>
                        </figure>
                        <section id='heading-2-1-1'>
                        <header>
                        <h4>
                            <a aria-hidden href='#heading-2-1-1'>Hypothalamic-Pituitary-Ovarian (HPO) axis</a>
                        </h4>
                        </header>
                        <div class='body'>
                            <p>GnRH is released from the hypothalamus <span class="underlined--offset">in pulses</span> which vary depending on the phase in the menstrual cycle.</p>
                            <p>GnRH pulse frequency is approximately <span class="underlined--offset">once per 90 min in the follicular phase</span>.</p>
                            <p>The pulses are <span class="underlined--offset">less frequent in the luteal phase</span>, occurring approximately <span class="underlined--offset">once in 4 h</span>.</p>
                            <p>GnRH acts on the anterior pituitary through the <span class="special-text">hypothalamohypophyseal portal system</span> to cause release of the gonadotropins - LH and FSH. These in turn act on the ovary to cause release of estrogen and progesterone.</p>
                            <p>Disorders that slow GnRH pulsatility, such as anorexia nervosa, result in failure of secretion of pituitary gonadotropins (LH and FSH) and a state of hypogonadal hypogonadism with failure of follicular development and amenorrhea.</p>
                            <p>Less severe reductions in GnRH pulse amplitude and frequency result in diminished FSH and LH with some follicular stimulation but not enough to result in ovulation but estradiol is secreted. This may occur in stress, hyperprolactinemia, excessive exercise or may be idiopathic.</p>
                            <p>An understanding of the normal cyclic fluctuations of the 2 gonadotropins (i.e., luteinizing hormone [LH], follicle-stimulating hormone [FSH]) and the primary female reproductive hormones (i.e., estrogen, progesterone) helps clarify the derangements associated with anovulation.</p>
                        </div>
                        </section>
                        <section id='heading-2-1-2'>
                            <header>
                            <h4>
                                <a aria-hidden href='#heading-2-1-2'>Pathophysiology of Anovulatory DUB</a>
                            </h4>
                            </header>
                            <div class='body'>
                                <p>With anovulation, estrogen levels rise as usual in the early phase of the cycle and because there is no ovulation, a corpus luteum never forms and progesterone is not produced.</p>
                                <p> There is a continuous unopposed estrogenic stimulation of the endometrium. Theendometrium as a result moves into a hyperproliferative state, ultimately outgrowing its blood supply. </p>
                                <p>This leads to irregular sloughing of the endometrium and excessive bleeding from spiral arteries that have not undergone physiological senescence.</p>
                                <figure>
                                    <img src="/figures/figures-06.png" alt="">
                                    <figcaption>fig. II. Dysfunctional uterine bleeding.</figcaption>
                                </figure>
                            </div>
                        </section>
                </section>
                <section id='heading-2-2'>
                    <header>
                    <h3>
                        <a aria-hidden href='#heading-2-2'>Ovulatory DUB</a>
                    </h3>
                    </header>
                    <div class='body'>
                        <p>This type of bleeding occurs cyclically, and thought to originate from defects in the control mechanisms of menstruation.</p>
                        <p>Occurs in women of reproductive age.</p>
                        <p>Occurs less commonly.</p>
                        <section id='heading-2-2-1'>
                        <header>
                        <h4>
                            <a aria-hidden href='#heading-2-2-1'>Normal menstrual cycle</a>
                        </h4>
                        </header>
                        <div class='body'>
                            <p>The normal cycle is <span class="special-text-3">28-29 days</span> (range of <span class="special-text-3">21-35d</span>).</p>
                            <p>Normal menstrual flow lasts <span class="special-text-3">3-7days</span>.</p>
                            <p>Average total blood loss of <span class="special-text-3">25-69 mL</span>. Flow longer than <span class="special-text-3">7 days</span> and blood loss exceeding <span class="special-text-3">80 mL</span> is considered abnormal.</p>
                            <p>The normal cycle is characterized by sequential growth, maturation and eventual sloughing of the endometrial mucosa. </p>
                            <p>This is produced by the cyclic release of estrogen and progesterone from the ovary and is orchestrated by the HPO axis.</p>
                            <figure>
                                <img src="/figures/figures-02.png" alt="">
                                <figcaption>fig. III. The first 14 days of a typical 28-day menstrual cycle are characterized by rising FSH levels.</figcaption>
                            </figure>
                            <p>FSH stimulates ovarian follicle development and the subsequent production of estrogen, primarily estradiol.</p>
                            <p>The endometrium, under the influence of estrogen, undergoes proliferation.</p>

                            <figure>
                                <img src="/figures/figures-03.png" alt="">
                                <figcaption>fig. IV. The menstrual cycle.</figcaption>
                            </figure>
                            <p>LH levels abruptly peak on day 12 or 13 in positive response to rising estrogen level. The LH surge stimulates-</p>
                            <ul>
                                <li>Ovulation (on or about day 14), and </li>
                                <li>Conversion of the ovulatory follicle to corpus luteum, which is responsible for progesterone production.</li>
                            </ul>
                            
                            <figure>
                                <img src="/figures/figures-04.png" alt="">
                                <figcaption>fig. V. The menstrual cycle.</figcaption>
                            </figure>
                            <p>Under the influence of progesterone, the endometrium is converted to a secretory state in preparation for implantation if fertilization of the ovum should occur. Progesterone is produced only if ovulation occurs. </p>
                            <figure>
                                <img src="/figures/figures-05.png" alt="">
                                <figcaption>fig. VI. Gonadotropins and ovarian hormone pattern in normal menstrual cycle.</figcaption>
                            </figure>

                            <p>As LH levels drop (in the absence of fertilization, production of human chorionic gonadotropin [HCG] by the developing conceptus does not occur), the corpus luteum regresses, estrogen and progesterone levels plummet, and the endometrium deteriorates and is sloughed.</p>
                        </div>
                        </section>
                        <section id='heading-2-2-2'>
                            <header>
                            <h4>
                                <a aria-hidden href='#heading-2-2-2'>Pathophysiology of Ovulatory DUB</a>
                            </h4>
                            </header>
                            <div class='body'>
                                <p>Bleeding occurs cyclically.</p>
                                <p> There is an increased rate of blood loss resulting from vasodilatation of the vessels supplying the endometrium due to <span class="underlined--offset">decreased vascular tone</span>, and prostaglandins have been strongly implicated. </p>
                                <p>Therefore, these women lose blood at rates about 3 times faster than women with normal menses.</p>

                                <div class="tips-card">
                                    <p class="tips-card-subtitle">note</p>
                                    <h4 class="tips-card-title">
                                      Prostaglandins involved in menstruation
                                    </h4>
                                    <p class="tips-card-content">
                                      <ul>
                                        <li>PGF<sub>2Î±</sub>: Vasoconstrictor and weak platelet aggregator.</li>
                                        <li>PGE<sub>2</sub>: Vasodilator and weak platelet anti-aggregator.</li>
                                        <li>PGD: Vasodilator and smooth muscle relaxant.</li>
                                        <li>PGI: Potent vasodilator and inhibitor of platelet aggregation.</li>
                                        <li>TXA<sub>2</sub>: Potent vasoconstrictor and platelet aggregator.</li>
                                      </ul>
                                        
                                    </p>
                                  </div>

                                <p>In women with normal blood flow the order of production of prostaglandins by the secretory endothelium is PGF2Î±/PGE2/PGD.</p>
                                <p>Increased amount of PGI (prostacyclin) are produced in the myometrium of DUB patients due to increased production of endoperoxidases.</p>
                            </div>
                        </section>

                        <section id='heading-2-2-3'>
                            <header>
                            <h4>
                                <a aria-hidden href='#heading-2-2-3'>Common terminologies for abnormal menstruation</a>
                            </h4>
                            </header>
                            <div class='body'>
                                <p><span class="special-text">Menorrhagia</span>: heavy bleeding, including prolonged menstrual periods (bleeding that lasts more than 7 days), or excessive bleeding (blood loss of greater than 80 ml per period) during a normal length period.Regular cycles, prolonged duration, excessive flow.</p>
                                <p><span class="special-text">Metrorrhagia</span>: bleeding at irregular intervals, particularly between expected menstrual periods. Frequent and irregular cycles.</p>
                                <p><span class="special-text">Menometrorrhagia</span>: prolonged or excessive uterine bleeding that occurs irregularly and more frequently than normal. Irregular, prolonged, excessive. </p>
                                <p><span class="special-text">Hypermenorrhea</span>: a menstrual period with excessively heavy flow. Regular, normal duration, excessive flow.</p>
                                <p><span class="special-text">Polymenorrhea</span>: frequent regular cycles that is shorter than 21 days.</p>
                                <p><span class="special-text">Oligomenorrhea</span>: Infrequent cycles. Uterine bleeding at regular intervals from 35 days to 6 months.</p>
                                <p><span class="special-text">Amenorrhea</span>:  primary amenorrhea is the failure of menses to occur by age 16, in the presence of normal growth and secondary sexual characteristics. Secondary amenorrhea is the cessation of uterine bleeding in a post-menarchial girl or a reproductive-aged woman for > 6 months.</p>
                                <p><span class="special-text">Postmenopausal bleeding</span>:  uterine bleeding that occurs more than 1 year after the last menses in a woman with ovarian failure.</p>
                            </div>
                        </section>
                </section>
            </div>
        </section>

        <section id='header-3'>
          <header>
            <h2>
              <a aria-hidden='true' href='#header-3'>Clinical presentation</a>
            </h2>
          </header>
          <div class='body'>
                  <p>Patients may present with a chronic light flow in the form of irregular, prolonged, or intermenstrual bleeding that is a nuisance but not a significant health threat. </p>
                  <p>Alternatively, patients can present with acute torrential hemorrhage requiring immediate medical attention. </p>
          </div>
        </section>

        <section id='header-4'>
          <header>
            <h2>
              <a aria-hidden='true' href='#header-4'>Differential diagnosis</a>
            </h2>
          </header>
          <div class='body'>
              <p>Abortion: Threatened, incomplete. The most common cause of abnormal uterine bleeding during the reproductive years is abnormal pregnancy.</p>
              <p>Ectopic Pregnancy</p>
              <p>Uterine Fibroids</p>
              <p>Pelvic inflammatory disease (PID)</p>
              <p>Polyps</p>
              <p>Adnexal Tumors: functional ovarian tumors</p>
              <p>Cervical cancer- it is the most common gynecological cancer affecting women of reproductive age in the world.</p>
              <p>Cervicitis</p>
              <p>Vaginitis</p>
              <p>Chlamydial genitourinary infections</p>
              <p>Endometrial carcinoma</p>
              <p>Endometriosis</p>
              <p>Endometritis </p>
              <p>Gestational trophoblastic neoplasia</p>
              <p>Hyperprolactinemia</p>
              <p>Hyperthyroidism</p>
              <p>Hypothyroidism</p>
              <p>Ovarian polycystic disease</p>
              <p>Clotting disorders</p>
              <p>Conditions affecting liver metabolism of estrogen can be associated with abnormal uterine bleeding.</p>
              <p>Coagulation factors deficiency e.g. Von Willebrand disease and factor XI deficiency initially might manifest during adolescence.</p>
              <p>Primary or secondary thrombocytopenia can be factors in the mature patient.</p>

          </div>
        </section>

        <section id='header-5'>
          <header>
            <h2>
              <a aria-hidden='true' href='#header-5'>Investigations</a>
            </h2>
          </header>
          <div class='body'>

            <ol>
              <li>Hematocrit/PCV</li>
              <li>Pelvic ultrasound: In obese patients with suboptimal pelvic examination, suspected ovarian or uterine pathology, to examine the status of the endometrium etc. </li>
              <li>Pregnancy test/Human chorionic gonadotropin.</li>
              <li>High vaginal swab/Endometrial swab for MCS</li>
              <li>Saline-infusion sonohysterography is also very useful in evaluating for intracavitary (submucosal) fibroids and endometrial polyps.</li>
              <li>Pap smear. </li>
              <li>Endometrial biopsy to rule out endometrial hyperplasia or cancer.</li>
              <li>Thyroid function test</li>
              <li>Hormonal assay: A hormonal complete evaluation in women with signs of hyperandrogenism, such as in polycystic ovarian syndrome, 21 hydroxylase deficiency, or ovarian or adrenal tumors. </li>
              <li>Women in menopausal transition usually can be followed without an extensive hormonal evaluation.</li>
              <li>Liver function test.</li>
            </ol>
          </div>
        </section>

        <section id='header-6'>
          <header>
            <h2>
              <a aria-hidden='true' href='#header-6'>Treatments</a>
            </h2>
          </header>
          <div class='body'>
                 <ul>
                  <li>Medical</li>
                  <li>Surgical</li>
                 </ul>
              <section id='heading-6-1'>
              <header>
                <h3>
                  <a aria-hidden href='#heading-6-1'>Medical treatments</a>
                </h3>
              </header>
              <div class='body'>
                      <p>Drugs used to treat DUB:</p>
                      <ul>
                        <li>Estrogens</li>
                        <li>Progestins </li>
                        <li>Androgens </li>
                        <li>Nonsteroidal anti-inflammatory drugs (NSAIDs)</li>
                        <li>Ergot derivatives</li>
                        <li>Antifibrinolytics</li>
                        <li>Gonadotropin-releasing hormone (GnRH) agonists </li>
                        <li>Desmopressin has been used to control bleeding when associated with diagnosed bleeding disorders.</li>
                      </ul>
                  <section id='heading-6-1-1'>
                  <header>
                    <h4>
                      <a aria-hidden href='#heading-6-1-1'>Combined oral contraceptives</a>
                    </h4>
                  </header>
                  <div class='body'>
                      <p>COCs contain both estrogen and progestins.</p>
                      <p>With COCs pills, bleeding usually is controlled within the first 24 hours, as the overgrown endometrium becomes pseudodecidualized, reestablish predictable bleeding patterns, decrease menstrual flow, and lower the risk of anemia.</p>
                      <p>Additional benefits, include decreased dysmenorrhea and ovarian cancer prophylaxis.</p>
                  </div>
                </section>
                <section id='heading-6-1-2'>
                  <header>
                    <h4>
                      <a aria-hidden href='#heading-6-1-2'>Estrogens</a>
                    </h4>
                  </header>
                  <div class='body'>
                      <p>Tablets or injections</p>
                      <p>E.g. IV Premarin</p>
                      <p>Useful for acute bleeding.</p>
                      <p><span class="special-text-3">25 mg</span> <span class="special-text">IV</span> <span class="underlined--offset">q4 hours(every 4 hours)</span> until bleeding slows.</p>
                      <p>Causes nausea, breast tenderness.</p>
                      <p><span class="underlined--offset">Give slowly or can cause vasovagal reaction or LOC</span>.</p>
                      <p>Must give <span class="special-text">progestins</span> for <span class="special-text-3">7- 10 days</span> after and then will have withdrawal bleed or start continuous OCPs.</p>
                  </div>
                </section>
                <section id='heading-6-1-3'>
                  <header>
                    <h4>
                      <a aria-hidden href='#heading-6-1-3'>Progestins</a>
                    </h4>
                  </header>
                  <div class='body'>
                      <p>Mainly indicated in patients with anovulatory bleeding to reverse the effects of estrogen mediated endometrial proliferation and induce endometrial maturation. </p>
                      <p>Cyclic progestin for <span class="special-text-3">10 days</span> <span class="underlined--offset">per month</span> using <span class="special-text">medroxyprogesterone acetate</span> (<span class="special-text-3">10 mg/d</span>) or <span class="special-text">norethindrone acetate</span> (<span class="special-text-3">2.5-5 mg/d</span>) provides predictable uterine withdrawal bleeding, but not contraception.</p>
                  </div>
                </section>

                <section id='heading-6-1-4'>
                  <header>
                    <h4>
                      <a aria-hidden href='#heading-6-1-4'>Non-steroidal anti-inflammatory drugs</a>
                    </h4>
                  </header>
                  <div class='body'>
                      <p>Blocks formation of prostacyclin, an antagonist of thromboxane, which is a substance that accelerates platelet aggregation and initiates coagulation. Prostacyclin is produced in increased amounts in menorrhagic endometrium. NSAIDS thus effectively decrease uterine blood flow. </p>
                      <p>Examples include <span class="special-text">Mefenamic</span> acid and <span class="special-text">Naproxen</span>.</p>
                  </div>
                </section>

                <section id='heading-6-1-5'>
                  <header>
                    <h4>
                      <a aria-hidden href='#heading-6-1-5'>GnRH agonists</a>
                    </h4>
                  </header>
                  <div class='body'>
                      <p>Induces postreceptor effects, which suppress gonadotropin release, with resultant hypogonadism resulting in amenorrhea, thus breaking cycle of abnormal bleeding in anovulatory patients. </p>
                      <p>Should not be used for more than 6months without adding a back-up therapy.</p>
                      <p>Prolonged use is associated with osteoporosis and other postmenopausal side effects.</p>
                  </div>
                </section>

                <section id='heading-6-1-6'>
                  <header>
                    <h4>
                      <a aria-hidden href='#heading-6-1-6'>Antifibrinolytics</a>
                    </h4>
                  </header>
                  <div class='body'>
                      <p>At the onset of menses, secretory endometrium contains a high concentration of plasminogen activator.</p>
                      <p>A reduction in menstrual blood loss has been demonstrated in some ovulatory patients taking <span class="special-text">Îµ-aminocaproic acid (EACA)</span> or <span class="special-text">aminomethylcyclohexane-carboxylic acid (AMCHA) tranexamic acid</span>, both potent antifibrinolytics.</p>
                  </div>
                </section>

                <section id='heading-6-1-7'>
                  <header>
                    <h4>
                      <a aria-hidden href='#heading-6-1-7'>Androgens </a>
                    </h4>
                  </header>
                  <div class='body'>
                      <p>Androgens have been used to treat mild to moderate bleeding, particularly ovulatory DUB, they function by altering endometrial tissue so that it becomes inactive and atrophic. </p>
                      <p>They offer no real advantage over other regimen, can cause irreversible signs of masculinization.</p>
                      <p>They are seldom used again.</p>
                      <p>They might stimulate erythropoiesis and clotting deficiency.</p>
                      <p>Examples are <span class="special-text">Danazol (Danocrine)</span> and <span class="special-text">Isoxazole</span>, derivative of 12 alpha-ethinyl testosterone</p>
                  </div>
                </section>
              </div>
            </section>
            <section id='heading-6-2'>
              <header>
                <h3>
                  <a aria-hidden href='#heading-6-2'>Surgical treatments</a>
                </h3>
              </header>
              <div class='body'>
                  <p>Surgical measures are reserved for situations when medical therapy has failed or is contraindicated.</p>
                  <p>D&C can be used to clear the endometrium in in a patient who fails to respond to hormonal management and also to obtain a biopsy but this is not commonly done anymore.</p>
                  <p><span class="special-text">Hysteroscopy</span> will aid in the treatment of endometrial polyps or the performance of directed uterine biopsies.</p>
                  <p><span class="special-text">Abdominal</span> or <span class="special-text">vaginal  hysterectomy</span> might be necessary in patients who have failed or declined hormonal therapy, have symptomatic anemia, and who experience a disruption in their quality of life from persistent, unscheduled bleeding.</p>
                  <p><span class="special-text">Endometrial ablation</span> is an alternative for those who wish to avoid hysterectomy or who are not candidates for major surgery. Ablation techniques are varied and can employ laser, rollerball, resectoscope, or thermal destructive modalities. </p>
                  <ul>
                    <li>Pretreat the patient with an agent, such as <span class="special-text">leuprolide acetate</span>, <span class="special-text">medroxyprogesterone acetate</span>, or <span class="special-text">danazol</span>, to thin the endometrium.</li>
                    <li>An endometrial biopsy is needed before ablation.</li>
                    <li>The ablation procedure is more conservative than hysterectomy and has a shorter recovery time.</li>
                    <li>Endometrial ablation is not a form of contraception. Some studies report up to a 5% pregnancy rate in post-ablation procedures.</li>
                  </ul>
                  <p>Some patients may have persistent bleeding and require repeat procedures or move on to hysterectomy.</p>
             </div>
            </section>
          </section>

          <div class="contact">
            <hr style="margin: 3rem 0;">
    
            <p>Send us a <a href="mailto:cohs.materia@gmail.com"><span class="special-text-2">mail</span></a> at 
             <br> cohs.materia@gmail.com.</p>
            <p>Or send your comments, corrections, explanations/clarifications and requests/suggestions to our 
             <br> <a href="" class="special-text-2" style="text-decoration: none;">WhatsApp group</a>.</p>
          </div>
    </article>
    </article>

  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p>obgyn.materia</p>
          
        </div>
    </div>
  </footer>
</body>
</html>
 